COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium (TIPSK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01404078
Recruitment Status : Completed
First Posted : July 27, 2011
Results First Posted : December 1, 2014
Last Update Posted : December 1, 2014
Population Health Research Institute
Information provided by (Responsible Party):
St. John's Research Institute

Brief Summary:

This is a randomized double blind 2x2 factorial controlled trial to evaluate efficacy tolerability of low strength Polycap versus two doses of low strength Polycap in patients with stable cardiovascular disease in reducing blood pressure and LDL.

To evaluate the tolerability and safety of low dose potassium supplementation compared to placebo in patients with stable cardiovascular disease.

Approximately 500 patients are planned to be randomized.

Condition or disease Intervention/treatment Phase
Ischemic Heart Disease Ischemic Stroke Peripheral Vascular Disease Type 2 Diabetes Mellitus Drug: Single Dose Polycap Drug: Double dose Polycap Not Applicable

Detailed Description:
Mean change in blood pressure between those taking 2capsules of the polycap versus one Difference in Rates of early discontinuation between 2 capsules of polycap versus one Rates of reported adverse effects among those taking the polycap

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 518 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A RCT With Factorial Design to Compare Safety and Efficacy of 2 Capsules of the Indian Polycap Versus a Single Capsule Along With or Without Oral Potassium Among Patients With Stable Cardiovascular Disease
Study Start Date : April 2010
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Potassium

Arm Intervention/treatment
Active Comparator: SD Polycap without potassium
Single dose polycap without pottasium
Drug: Single Dose Polycap
Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
Other Name: Polycap

Experimental: DD Polycap plus potassium
Double Dose polycap with potassium
Drug: Double dose Polycap
2 Capsules of low strength polycap with 30mEq of Potassium
Other Name: Full dose polycap

Primary Outcome Measures :
  1. BLOOD PRESSURE LIPIDS [ Time Frame: 8 weeks ]
    Amongst patients with cardiovascular disease or type 2 diabetes, the study aims to test the safety and efficacy of giving double dose of polycap versus a single dose of polycap for 8 weeks; efficacy to lower blood pressure and elevated lipids and safety assessed as difference with tolerance to double dose of polycap compared to a single dose.

  2. Tolerability of a Double Dose of Half Strength Polycap [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Blood Pressure Reduction and Lipid Lowering in Type 2 Diabetics [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Individuals 40 years and above, with a seated blood pressure > 130/80 mm Hg on two consecutive readings (or BP > 120/80 mm Hg in patients under treatment with 2 or more antihypertensive medication) with one of the following

    1. Coronary artery disease; previous myocardial infarction (>7 days post uncomplicated MI), or
    2. Ischemic heart disease with significant ECG changes or a positive stress test, or
    3. Stable angina or unstable angina and with documented evidence of multi-vessel (angiography or ECG or CT angiography) coronary artery disease, or
    4. PTCA or CABG Surgery >30 days before informed consent.
    5. Cerebrovascular disease; Previous Ischemic stroke or Transient Ischemic Attacks >30 days before informed consent.
    6. High risk diabetes mellitus defined as HbA1C >7.5%, with microalbuminuria or blood pressure >140/90 mm Hg.
    7. Peripheral artery disease defined as a current or prior history of: physician diagnosed intermittent claudication or vascular surgery for atherosclerotic disease or an ankle/arm systolic blood pressure ratio ≤ 0.90 in either leg at rest, or angiographic or doppler study demonstrating ≥ 70% stenosis in a noncardiac artery.
  2. Those who provide informed consent and can comply with medications and follow-up visits.

Exclusion Criteria:

  1. Known hypersensitivity or intolerance to any of the study medications or a clear indication for full doses of beta blockers, RAAS blockers (ACEi, ARBs, Renin inhibitors, etc.), diuretics and statins.
  2. History of bleeding or having hemorrhagic stroke anytime in the past or a need for continued anticoagulation therapy.
  3. Patients having indication for higher doses of aspirin or needing more than 75mg of clopidogrel daily.
  4. Have significant bradycardia (heart rate <50 beats/min) or second- or third-degree heart block without a pacemaker.
  5. Planned cardiac surgery or PTCA or any non-cardiac surgery <3months of eligibility assessment.
  6. Heart transplant recipient.
  7. Renal dysfunction defined as serum creatinine >2 mg/dL and/or serum potassium >5.0 mEq/L.
  8. Patients aged >70 years, with mild renal dysfunction defined as serum creatinine >124 µmol/L (1.4 mg/dL) or eGFR <45 ml/min/1.73 m2.
  9. Hepatic dysfunction, SGOT or SGPT > 3 x ULN.
  10. Taking another experimental drug or within 30days of last dose of the experimental drug.
  11. Peptic ulcer disease with bleed, or bleeding diathesis.
  12. Bronchial asthma or Chronic Obstructive Pulmonary Disease with asthma.
  13. Gout, rheumatoid arthritis or other chronic inflammatory disease requiring long-term medications with NSAIDs.
  14. Any history of muscular pain, other pathology of the muscles or past history of muscular pain secondary to taking statins or fibrates.
  15. Pregnancy or lactating or women of childbearing potential with inadequate contraception.
  16. Inability to attend follow up visits (due to significant disability, inadequate address or contact details, subject from a far off place, psychiatric illness etc.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01404078

Sponsors and Collaborators
St. John's Research Institute
Population Health Research Institute
Layout table for investigator information
Principal Investigator: Dr.Prem - Pais, MD St.Johns Research Institute
Additional Information:
Layout table for additonal information
Responsible Party: St. John's Research Institute Identifier: NCT01404078    
Other Study ID Numbers: TIPS K
CTRI/2010/091/000054 ( Registry Identifier: Clinical Trials Registry of India )
First Posted: July 27, 2011    Key Record Dates
Results First Posted: December 1, 2014
Last Update Posted: December 1, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Vascular Diseases
Myocardial Ischemia
Coronary Artery Disease
Peripheral Vascular Diseases
Peripheral Arterial Disease
Pathologic Processes
Cardiovascular Diseases
Coronary Disease
Arterial Occlusive Diseases